An Open-Label, Multicenter, Extension Study to Evaluate the Long Term Safety of Intravenous CR845 in Hemodialysis Patients With Chronic Kidney Disease-Associated Pruritus
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs Difelikefalin (Primary)
- Indications Pruritus
- Focus Adverse reactions; Registrational
- Sponsors Cara Therapeutics
- 19 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Aug 2019 According to a Cara Therapeutics media release, this trial is expected to support worldwide registration filings of KORSUVA Injection.
- 07 Aug 2019 According to a Cara Therapeutics media release, approximately 165 patients having completed at least 6 months of treatment and over 50% of these patients having completed 1 year of treatment.